{"id":5896,"date":"2025-05-19T14:51:44","date_gmt":"2025-05-19T14:51:44","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=rkd-news&#038;p=5896"},"modified":"2025-10-14T13:06:13","modified_gmt":"2025-10-14T13:06:13","slug":"fsgs-clinical-trial-endpoints-proteinuria","status":"publish","type":"rkd-news","link":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/","title":{"rendered":"Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria"},"content":{"rendered":"<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n    <img decoding=\"async\" width=\"643\" height=\"357\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-urine-cup-background.webp\" class=\"a-img a-img--right h-full\" alt=\"Hero Section Background Image\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-urine-cup-background.webp 643w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-urine-cup-background-300x167.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-urine-cup-background-290x161.webp 290w\" sizes=\"auto, (max-width: 643px) 100vw, 643px\" \/>    <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\r\n\t<section style=\"padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;margin-top:calc(-120px * var(--scale));\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\"><\/i> Published on May 9, 2025\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics: <\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">FSGS<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\n\t\t<div class=\"info-block-box\">\n\t\t\t\n\t\t\t\t\t<\/div>\n\n\t\t\n\t\t<div class=\"info-block-share\">Share:\n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Ffsgs-clinical-trial-endpoints-proteinuria%2F&#038;text=Exploring+Clinical+Trial+Endpoints+in+FSGS%3A+Spotlight+on+Proteinuria\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Ffsgs-clinical-trial-endpoints-proteinuria%2F&#038;title=Exploring+Clinical+Trial+Endpoints+in+FSGS%3A+Spotlight+on+Proteinuria\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Ffsgs-clinical-trial-endpoints-proteinuria%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=Exploring%20Clinical%20Trial%20Endpoints%20in%20FSGS%3A%20Spotlight%20on%20Proteinuria&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Ffsgs-clinical-trial-endpoints-proteinuria%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div class=\"modal modal-request-copy\" style=\"display: none;\" id=\"modal-request-copy\">\n\t<div class=\"modal__backdrop\">\n\t\t<div class=\"modal__card\">\n\t\t\t<button class=\"modal__close btn-close\" aria-label=\"Close modal\">&times;<\/button>\n\t\t\t<h4 class=\"has-heading-3-font-size\">Request a copy<\/h4>\n\t\t\t\n<div class=\"wpcf7 no-js\" id=\"wpcf7-f2317-o1\" lang=\"en-US\" dir=\"ltr\" data-wpcf7-id=\"2317\">\n<div class=\"screen-reader-response\"><p role=\"status\" aria-live=\"polite\" aria-atomic=\"true\"><\/p> <ul><\/ul><\/div>\n<form action=\"\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/5896#wpcf7-f2317-o1\" method=\"post\" class=\"wpcf7-form init wpcf7-acceptance-as-validation\" aria-label=\"Contact form\" novalidate=\"novalidate\" data-status=\"init\">\n<fieldset class=\"hidden-fields-container\"><input type=\"hidden\" name=\"_wpcf7\" value=\"2317\" \/><input type=\"hidden\" name=\"_wpcf7_version\" value=\"6.1.1\" \/><input type=\"hidden\" name=\"_wpcf7_locale\" value=\"en_US\" \/><input type=\"hidden\" name=\"_wpcf7_unit_tag\" value=\"wpcf7-f2317-o1\" \/><input type=\"hidden\" name=\"_wpcf7_container_post\" value=\"0\" \/><input type=\"hidden\" name=\"_wpcf7_posted_data_hash\" value=\"\" \/>\n<\/fieldset>\n<div class=\"cf7-fields-wrapper\">\n  <div class=\"form-two-cols\">\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-first-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-first-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"First Name*\" value=\"\" type=\"text\" name=\"request-first-name\" \/><\/span>\n    <\/div>\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-last-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-last-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Last Name*\" value=\"\" type=\"text\" name=\"request-last-name\" \/><\/span>\n    <\/div>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-your-email\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-email wpcf7-validates-as-required wpcf7-text wpcf7-validates-as-email\" id=\"request-your-email\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Email*\" value=\"\" type=\"email\" name=\"request-your-email\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-title\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Title*\" value=\"\" type=\"text\" name=\"request-title\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-agree\"><span class=\"wpcf7-form-control wpcf7-acceptance\"><span class=\"wpcf7-list-item\"><label><input type=\"checkbox\" name=\"request-agree\" value=\"1\" class=\"required\" id=\"request-agree\" aria-invalid=\"false\" \/><span class=\"wpcf7-list-item-label\">All personal data will be processed by or on behalf of Travere to provide access to company information and to respond to requests. Travere will retain personal data only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal data is private and will not disseminate it to third parties who are not providing services to Travere. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\">Travere privacy policies<\/a>.<\/span><\/label><\/span><\/span><\/span>\n  <\/div>\n  <div class=\"form-group text-right\">\n    <input class=\"wpcf7-form-control wpcf7-submit has-spinner btn\" id=\"request-submit\" type=\"submit\" value=\"Yes, continue\" \/>\n  <\/div>\n<\/div><div class=\"wpcf7-response-output\" aria-hidden=\"true\"><\/div>\n<\/form>\n<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div> <\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section style=\"padding-top:calc(30px * var(--scale));padding-right:0px;padding-bottom:0px;padding-left:0px;\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div style=\"height:48px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">In this issue we:<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li><a href=\"#h-collaborative-efforts-within-the-nephrology-community-are-driving-progress-in-fsgs-research-and-enhancing-clinical-studies-7-10\">Discuss the limits of historically and currently recognized clinical endpoints in FSGS studies<\/a><\/li>\n<li><a href=\"#h-collaborative-efforts-within-the-nephrology-community-are-driving-progress-in-fsgs-research-and-enhancing-clinical-studies-7-10\">Describe recent milestones in FSGS research<\/a><\/li>\n<li><a href=\"#h-in-addition-to-highlighting-proteinuria-as-a-feasible-endpoint-for-fsgs-clinical-trials-the-parasol-project-set-out-to-better-understand-proteinuria-thresholds-by-assessing-fsgs-data-from-around-the-world-10-nbsp\">Assess the utility and clinical implication of proteinuria as the endpoint in FSGS trials<\/a><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:45px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"event-video\" id=\"video\">\n\t\t\t<p class=\"has-heading-3-font-size\">Welcome by Dr. Anna Gaddy<\/p>\n\t\t\n\t<a href=\"#\" class=\"event-video--img\" style=\"background-image: url('https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Spotlight-on-proteinuria-video.webp');\">\n\t\t<span class=\"icon2-play\" aria-hidden=\"true\"><\/span>\n\t<\/a>\n\t\n\t<div class=\"event-video--vimeo\"><\/div>\n\t\n\t<\/div>\n\n<script src=\"https:\/\/player.vimeo.com\/api\/player.js\"><\/script>\n<script>\n\tdocument.addEventListener(\"DOMContentLoaded\", function() {\n\t\tconst imgLink = document.querySelector(\".event-video--img\");\n\t\tconst vimeoDiv = document.querySelector(\".event-video--vimeo\");\n\t\tlet iframeExists = false;\n\t\tlet player;\n\n\t\timgLink.addEventListener(\"click\", function(event) {\n\t\t\tevent.preventDefault();\n\n\t\t\tif (!iframeExists) {\n\t\t\t\tconst iframe = document.createElement(\"iframe\");\n\t\t\t\tiframe.src = \"https:\/\/player.vimeo.com\/video\/1079838137\";\n\t\t\t\tiframe.frameBorder = \"0\";\n\t\t\t\tiframe.allow = \"autoplay; fullscreen\";\n\t\t\t\tiframe.allowFullscreen = true;\n\t\t\t\tvimeoDiv.appendChild(iframe);\n\t\t\t\t\n\t\t\t\tplayer = new Vimeo.Player(iframe);\n\t\t\t\tplayer.play();\n\t\t\t\tiframeExists = true;\n\t\t\t}\n\n\t\t\tvimeoDiv.style.display = \"block\";\n\t\t\timgLink.style.display = \"none\";\n\t\t});\n\n\t\tvimeoDiv.addEventListener(\"click\", function() {\n\t\t\tconst iframe = vimeoDiv.querySelector(\"iframe\");\n\t\t\tiframe.contentWindow.postMessage('{\"method\":\"play\"}', 'https:\/\/player.vimeo.com\/video\/1079838137');\n\t\t});\n\t});\n<\/script>\n\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-focal-segmental-glomerulosclerosis-fsgs-is-a-rare-progressive-kidney-condition-with-no-fda-approved-pharmacologic-therapies-1\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Focal segmental glomerulosclerosis (FSGS) is a rare, progressive kidney condition with no FDA-approved pharmacologic therapies<sup>1<\/sup><\/mark><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>FSGS is a histopathologic pattern of injury seen on kidney biopsy, reflecting underlying podocytopathy and characterized by segmental glomerular sclerosis, variable degrees of proteinuria, and, in some cases, nephrotic syndrome.<sup>2,3<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-FSGS.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"718\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-FSGS.webp\" class=\"attachment-full size-full\" alt=\"Proteinuria in FSGS\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-FSGS.webp 1200w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-FSGS-300x180.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-FSGS-1024x613.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-FSGS-768x460.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-FSGS-290x174.webp 290w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p style=\"text-align: left;\">Figure. Proteinuria in FSGS<\/p><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:0px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Given the lack of approved treatments, there remains a need to address the high clinical, humanistic, and economic burden of FSGS.<sup>4-6<\/sup> While clinical studies are key to identifying effective and safe therapies for FSGS, studies may be met with several challenges.<sup>1,7<\/sup><\/p>\n<ul>\n<li>As FSGS is a rare condition, it has a smaller patient population, leading to some studies facing difficulties in patient recruitment<sup>1,7<\/sup><\/li>\n<li>FSGS is also a heterogeneous condition, potentially making it difficult to evaluate targeted therapies in a diverse patient population<sup>1<\/sup><\/li>\n<li>Historically, there was uncertainty around appropriate clinical trial endpoints<sup>7<\/sup><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:45px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"podcast-categories\">\n\t\t<div class=\"podcast-category\">\n\t\t<div class=\"podcast-category-img\">\n\t\t\t<img decoding=\"async\" width=\"2560\" height=\"2560\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-300x300.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-1024x1024.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-150x150.webp 150w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-768x768.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-1536x1536.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-2048x2048.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-290x290.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t<\/div>\n\t\t<div class=\"podcast-category-content\">\n\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics: <\/p>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">FSGS<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<p class=\"has-heading-4-font-size\"><br \/><strong>Introduction to FSGS<\/strong><\/p>\n\t\t\t<p>Understanding FSGS: Tune in to Dr. Trachtman&#039;s overview and clinical insights on FSGS.<\/p>\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/fsgs-introduction\/\" class=\"btn\" aria-label=\"Listen now\">Listen now<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div style=\"height:45px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-collaborative-efforts-within-the-nephrology-community-are-driving-progress-in-fsgs-research-and-enhancing-clinical-studies-7-10\" style=\"margin-right:0px;margin-bottom:0px;margin-left:0px\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Collaborative efforts within the nephrology community are driving progress in FSGS research and enhancing clinical studies<sup>7-10<\/sup><\/mark><\/span><\/h3>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Advancements in FSGS include:<\/p>\n<ul>\n<li>A better understanding of the pathology<sup>8<\/sup><\/li>\n<li>A notable increase in emerging investigational therapies<sup>8<\/sup><\/li>\n<li>The identification of proteinuria as a primary clinical trial endpoint and a marker of disease progression<sup>9,10<\/sup><\/li>\n<\/ul>\n<p>In 2018, the Kidney Health Initiative (KHI) Working Group evaluated potential short-term and intermediate endpoints from FSGS studies and identified proteinuria as a key endpoint.<sup>7<\/sup> The KHI and FDA working group believed that achieving complete remission (CR) of proteinuria (<0.3 g\/day) could act as a surrogate endpoint for traditional approval of new FSGS therapies.<sup>9<\/sup><\/p>\n<p>Several studies supported achievement of CR of proteinuria as the strongest indicator for a better long-term FSGS prognosis.<sup>11-13<\/sup> Reaching CR of proteinuria was associated with prolonged kidney survival and lower risk of kidney failure in patients with FSGS.<sup>12-14<\/sup><\/p>\n<p>In line with those findings, the 2021 Kidney Disease Improving Global Outcomes (KDIGO) guideline recommended CR of proteinuria as the optimal therapeutic goal for FSGS.<sup>3<\/sup><\/p>\n<p>In 2024, the FDA, NephCure, the International Society of Glomerular Disease (ISGD), the KHI, and the National Kidney Foundation (NKF) partnered to hold the PARASOL Scientific Workshop.<sup>15<\/sup> The objective was to evaluate the use of proteinuria and estimated glomerular filtration rate (eGFR) as surrogate endpoints for kidney failure (KF), as KF is unfeasible to use in clinical trials due to the nature of FSGS.<sup>15<\/sup><\/p>\n<p>Findings from PARASOL suggest that an eGFR slope endpoint is impractical to implement in clinical trials, whereas proteinuria is a biologically plausible and clinically meaningful surrogate endpoint with a strong predictive value for kidney failure risk.<sup>10<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Endpoint-Considerations-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Endpoint-Considerations-scaled.webp\" class=\"attachment-full size-full\" alt=\"Considerations for eGFR and proteinuria as FSGS clinical study endpoints\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Endpoint-Considerations-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Endpoint-Considerations-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Endpoint-Considerations-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Endpoint-Considerations-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Endpoint-Considerations-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Endpoint-Considerations-2048x1152.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Endpoint-Considerations-290x163.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p style=\"text-align: left;\">Figure. Considerations for eGFR and proteinuria as FSGS clinical study endpoints<sup>2,10<\/sup><\/p><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>PARASOL data also suggests that using proteinuria as an endpoint could allow for more feasible study sample sizes.<sup>10<\/sup> For example, to detect a treatment effect of 15%, one would only need approximately 210 patients per treatment group, supporting both the assessment of efficacy and the feasibility of conducting trials in the typically small FSGS patient population.<sup>10<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-in-addition-to-highlighting-proteinuria-as-a-feasible-endpoint-for-fsgs-clinical-trials-the-parasol-project-set-out-to-better-understand-proteinuria-thresholds-by-assessing-fsgs-data-from-around-the-world-10-nbsp\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">In addition to highlighting proteinuria as a feasible endpoint for FSGS clinical trials, the PARASOL project set out to better understand proteinuria thresholds by assessing FSGS data from around the world<sup>10&nbsp;<\/sup><\/span><\/mark><\/h4>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>The PARASOL project analyzed data from several participating registries.<sup>10<\/sup> Achieving proteinuria reduction was strongly associated with a significant reduction in risk of kidney failure, and findings were robust across subgroups.<sup>10<\/sup> Similar behavior was seen across proteinuria thresholds ranging from 0.7 to 1.5 g\/g.<sup>10<\/sup> For patients with a high risk of FSGS progression, experiencing some level of proteinuria reduction represented substantial biological improvement and slower disease progression.<sup>10<\/sup> Those who achieved CR of proteinuria had the lowest risk of kidney failure within 7 years.<sup>10<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Kidney-Failure.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1104\" height=\"356\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Kidney-Failure.webp\" class=\"attachment-full size-full\" alt=\"PARASOL: Proteinuria response thresholds and risk of kidney failure\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Kidney-Failure.webp 1104w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Kidney-Failure-300x97.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Kidney-Failure-1024x330.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Kidney-Failure-768x248.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/Kidney-Failure-290x94.webp 290w\" sizes=\"auto, (max-width: 1104px) 100vw, 1104px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p style=\"text-align: left;\">Figure. PARASOL: Proteinuria response thresholds and risk of kidney failure<sup>16<\/sup><\/p><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>PARASOL data were independently validated in the UK FSGS Registry of Rare Kidney Disease (RaDaR) cohort.<sup>10<\/sup> Overall recent findings regarding endpoints in FSGS are paving the way for significant clinical trial advancements.<sup>10<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:48px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>In recent years, organizations have partnered to advance FSGS research and improve clinical trial design in an effort to tackle the high clinical, humanistic, and economic burden of FSGS. <sup>4-7,9,10,15<\/sup> Identification of proteinuria reduction as a primary endpoint for FSGS studies has been a pivotal advancement.<sup>9,10<\/sup> Recently, PARASOL and RaDaR demonstrated that proteinuria reduction was significantly associated with improvement of renal outcomes, underscoring the clinical meaningfulness and importance as a primary endpoint.<sup>10<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:48px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-ocean-blue-color has-text-color has-link-color wp-elements-51cd0c4ef90fd47f09aee67a5374353a\" id=\"h-references\" style=\"margin-bottom:calc(30px * var(--scale))\"><strong>References<\/strong><\/h5>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list has-small-font-size\">\n<li class=\"has-small-font-size\">Trachtman H. <em>Expert Opin Emerg Drugs<\/em>. 2020;25(3):367-375.<\/li>\n\n\n\n<li class=\"has-small-font-size\">D&#8217;agati VD et al. <em>N<\/em> <em>Engl J<\/em> <em>Med<\/em>. 2011;365(25):2398-2411.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int. 2021;100(4S):S1-S276.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Gipson DS et al. <em>JAMA Netw Open<\/em>. 2022;5(8):e2228701.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Szklarzewicz J et al. Poster presented at: European Renal Association Congress 2023; June 15-18. 2023; Milan, Italy.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Bensink ME et al. <em>Kidney Med<\/em>. 2024;6(2):100760.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Gale D. Presented at: American Society of Nephrology Kidney Week 2024. October 24-27, 2024. San Diego, CA.<\/li>\n\n\n\n<li class=\"has-small-font-size\">De Cos M et al. <em>Kidney Int Rep<\/em>. 2023;8(1):30-35.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Mariani LH et al. <em>Am J Kidney Dis.<\/em> 2024.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Smith AR. Presented at: American Society of Nephrology Kidney Week 2024. October 24-27, 2024. San Diego, CA.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Troyanov S et al.<em> J Am Soc Nephrol<\/em>. 2005;16(4):1061-1068.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Troost JP et al. <em>Am J Kidney Dis.<\/em> 2021;77(2):216-225.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Troost JP et al. Clin <em>J Am Soc Nephrol<\/em>. 2018;13(3):414-421.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Saleem MA et al. Poster presented at: American Society of Nephrology Kidney Week; November 4-7, 2021. Virtual. PC1529.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Food and Drug Administration. Proteinuria and GFR as Clinical Trial Endpoints in Focal Segmental Glomerulosclerosis: A Scientific Workshop. Accessed 21 March 2025. <a href=\"https:\/\/www.fda.gov\/drugs\/proteinuria-and-gfr-clinical-trial-endpoints-focal-segmental-glomerulosclerosis-scientific-workshop\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.fda.gov\/drugs\/proteinuria-and-gfr-clinical-trial-endpoints-focal-segmental-glomerulosclerosis-scientific-workshop.<\/a><\/li>\n\n\n\n<li class=\"has-small-font-size\">Tumlin J et al. Presented at: National Kidney Foundation Spring Clinical Meetings 2025; April 10-13, 2025; Boston, USA. LB-07.<\/li>\n<\/ol>\n<\/div>\n\n\n<p class=\"has-text-align-right has-small-font-size\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\">MA-DS-25-0017 | May 2025<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":5867,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":""},"product":[142],"therapeutic_area":[97],"disease_area":[186],"study_registry":[],"study_type":[183],"resource_type":[208],"class_list":["post-5896","rkd-news","type-rkd-news","status-publish","has-post-thumbnail","hentry","product-non-product-disease-state","therapeutic_area-neph","disease_area-fsgs","study_type-rwe","resource_type-newsletter"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rare Kidney Disease News | Spotlight on Proteinuria in FSGS Trials<\/title>\n<meta name=\"description\" content=\"Learn more about proteinuria as a primary clinical trial endpoint for focal segmental glomerulosclerosis studies.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria\" \/>\n<meta property=\"og:description\" content=\"Learn more about proteinuria as a primary clinical trial endpoint for focal segmental glomerulosclerosis studies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-14T13:06:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-urine-cup-background.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"643\" \/>\n\t<meta property=\"og:image:height\" content=\"357\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/fsgs-clinical-trial-endpoints-proteinuria\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/fsgs-clinical-trial-endpoints-proteinuria\\\/\",\"name\":\"Rare Kidney Disease News | Spotlight on Proteinuria in FSGS Trials\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/fsgs-clinical-trial-endpoints-proteinuria\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/fsgs-clinical-trial-endpoints-proteinuria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/proteinuria-in-urine-cup-background.webp\",\"datePublished\":\"2025-05-19T14:51:44+00:00\",\"dateModified\":\"2025-10-14T13:06:13+00:00\",\"description\":\"Learn more about proteinuria as a primary clinical trial endpoint for focal segmental glomerulosclerosis studies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/fsgs-clinical-trial-endpoints-proteinuria\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/fsgs-clinical-trial-endpoints-proteinuria\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/fsgs-clinical-trial-endpoints-proteinuria\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/proteinuria-in-urine-cup-background.webp\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/proteinuria-in-urine-cup-background.webp\",\"width\":643,\"height\":357,\"caption\":\"Proteinuria in urine cup\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/fsgs-clinical-trial-endpoints-proteinuria\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Proteinuria as a Key FSGS Surrogate Endpoint\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rare Kidney Disease News | Spotlight on Proteinuria in FSGS Trials","description":"Learn more about proteinuria as a primary clinical trial endpoint for focal segmental glomerulosclerosis studies.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria","og_description":"Learn more about proteinuria as a primary clinical trial endpoint for focal segmental glomerulosclerosis studies.","og_url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-14T13:06:13+00:00","og_image":[{"width":643,"height":357,"url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-urine-cup-background.webp","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/","url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/","name":"Rare Kidney Disease News | Spotlight on Proteinuria in FSGS Trials","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/#primaryimage"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/#primaryimage"},"thumbnailUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-urine-cup-background.webp","datePublished":"2025-05-19T14:51:44+00:00","dateModified":"2025-10-14T13:06:13+00:00","description":"Learn more about proteinuria as a primary clinical trial endpoint for focal segmental glomerulosclerosis studies.","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/#primaryimage","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-urine-cup-background.webp","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/proteinuria-in-urine-cup-background.webp","width":643,"height":357,"caption":"Proteinuria in urine cup"},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/fsgs-clinical-trial-endpoints-proteinuria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"Proteinuria as a Key FSGS Surrogate Endpoint"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 10:13:26","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"therapeutic_area","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/5896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/rkd-news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media\/5867"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=5896"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=5896"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=5896"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=5896"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=5896"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=5896"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=5896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}